Gilead Sciences Combination Therapy (NASDAQ:GILD)
Gilead Sciences, Inc. (NASDAQ:GILD) in partnership with the GlaxoSmithKline plc (ADR) (NYSE:GSK) today has announced their plans for an international clinical trial to study the combination therapy versus monotherapy in a first-line treatment setting for pulmonary arterial hypertension (PAH). The study will be called AMBITION and it derives its name from AMBrIsentan and Tadalafil in subjects with pulmonary arterial hypertensION. The clinical trial will be a double blind, multicenter study with more than 300 PAH patients who will be receiving a randomized combination of ambrisentan and tadalafil or monotherapy. Currently both the companies are working with the regulatory agencies and PAH research communities to finalize the details of their study. Enrollment for the study is expected to begin in 2010 after both the companies finalize and get approvals from regulatory agencies.
Gilead Sciences is a biopharmaceutical company that discovers, develops, and commercializes innovative therapeutics for unmet medical needs. The goal of Gilead Sciences is to advance the care of patients who are suffering from life threatening diseases around the world. This combination therapy clinical trial will help Gilead Sciences to know more about PAH and how to come out with a better therapy to treat PAH diseases. PAH is a disease that is characterized by constriction of the blood vessels in the lungs leading to high pulmonary arterial pressures. These high pressures make it difficult for the heart to pump blood through lungs to be oxygenated. Currently there are 200,000 patients suffering from PAH worldwide and they suffer from shortness of breath and many of them ultimately die of heart failure.
